Malignant syndrome in Parkinson's disease: concept and review of the literature
Introduction
Malignant syndrome occurring during the course of treatment of Parkinson's disease (PD) was first described by Toru et al. [1]. They reported a 63-year-old woman diagnosed of PD who had developed a symptom complex consisting of extrapyramidal symptoms, altered consciousness, diaphoresis, fever, and increased serum creatine kinase (CK) following the discontinuation of large doses of combined anti-parkinsonian drugs. Their patient recovered uneventfully after treatment with levodopa/carbidopa.
Then Fujitake et al. [2] reported seven patients with PD and one patient with olivopontocerebellar atrophy (OPCA) who developed acutely high fever, altered consciousness, marked rigidity, and shock in some of the patients during the course of levodopa treatment. All of them showed a marked increase in serum CK, had developed drug related psychotic symptoms prior to the onset of malignant syndrome and levodopa or amantadine HCl was reduced in six out of the eight patients. Their clinical features were essentially similar to those of neuroleptic malignant syndrome reported in the literature [3], [4], [5]. Their patients recovered after treatment with intravenous fluid infusion, levodopa, bromocriptine and, in some patients, dantrolene sodium. The authors concluded that acute reduction in both the nigrostriatal and hypothalamic cerebral dopaminergic transmission, was responsible for this syndrome.
In the same year, Sechi et al. [6] reported a patient affected with idiopathic PD and levodopa-induced dyskinesias who had developed fatal hyperpyrexia after simultaneous levodopa withdrawal and decrease in the dosage of diphenhydramine. The clinical features were essentially similar to those of neuroleptic malignant syndrome. They suggested that the rapid decrease in dopaminergic activity might have caused this syndrome.
Since then, many similar cases have been reported in the literature. Figa-Talamanca et al. [7] reported a patient who had developed hyperthermia as a complication following discontinuation of levodopa/carbidopa and bromocriptine. They suggested that impaired nigrostriatal, hypothalamic, and mesolimbic dopaminergic functions could be involved in the pathogenesis.
In the same year, Friedman et al. [8] reported three patients resembling neuroleptic malignant syndrome. Each patient had a long history of PD treated with levodopa–carbidopa. Two patients developed the syndrome when administration of the drug was temporarily discontinued. One developed the syndrome before a ‘drug holiday,’ and then died during the holiday. This patient is the second reported case to die of malignant syndrome after levodopa withdrawal.
Gibb and Griffith [9] reported a patient with PD and schizophrenia. This 60-year-old woman had been taking levodopa/carbidopa and thioridazine. Five months after thioridazine had been stopped levodopa/carbidopa was withdrawn. One week later she developed features of neuroleptic malignant syndrome accompanied by myoglobinuric renal failure. Post-mortem examination showed nigral degeneration with Lewy bodies. No additional abnormality was detected that could explain her malignant syndrome.
Di Rosa et al. [10] reported a patient who developed malignant syndrome during a drug holiday. They ascribed the hyperthermia to functional hypothalamic deficiency resulting in defective heat dispersion due to the lack of cutaneous vasodilatation.
There are many additional reports of MS in similar patients induced by levodopa withdrawal [11], [12], [13].
Section snippets
Clinical features
Clinical features of levodopa-withdrawal malignant syndrome consist of worsening parkinsonism with a marked increase in muscle tone, elevation of the body temperature, altered consciousness, marked elevation of serum CK, and autonomic dysfunction such as tachycardia, perspiration, loss of sweating, non-paralytic ileus, and fluctuation of the blood pressure (Table 1). Clinical features of levodopa withdrawal malignant syndrome are essentially very similar to those of neuroleptic malignant
Malignant syndrome in secondary parkinsonism
The malignant syndrome due to levodopa withdrawal has been reported in multiple system atrophy (MSA) after discontinuation of levodopa [26], [27], [28]. It is interesting to note that while levodopa does not effectively control the motor symptoms of MSA, nevertheless, an abrupt reduction can still cause malignant syndrome. Clinical features of malignant syndrome in MSA were essentially similar to those of malignant syndrome in PD.
References (56)
- et al.
Neuroleptic malignant syndrome. Review and analysis of 115 cases
Biol Psychiatr
(1987) - et al.
Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia
J Biol Chem
(1988) - et al.
Aetiology of malignant hyperthermia
Br J Anesthet
(1988) - et al.
Sulpiride increases and dopamine decreases intracranial temperature in rat when injected in the lateral hypothalamus: an animal model for the neuroleptic malignant syndrome?
Brain Res
(1995) - et al.
Successful treatment of an episode of malignant hyperthermia using a large dose of dantrolene
J Clin Anesthet
(1993) - et al.
Frequency of neuroleptic malignant syndrome in a large psychiatric hospital in Moscow
Eur Psychiatr
(2000) - et al.
No association between the neuroleptic malignant syndrome and mutations in the RYR1 gene associated malignant hyperthermia
J Neurol Sci
(1996) Neuroleptic malignant syndrome and malignant hyperthermia. Important issues for the medical consultant
Med Clin North Am
(1993)- et al.
Malignant hyperthermia and central core disease: analysis of two families with heterogeneous clinical expression
Neuromusc Disord
(1993) - et al.
Neuroleptic malignant syndrome-like state following a withdrawal of antiparkinsonian drugs
J Nerv Ment Dis
(1981)
Neuroleptic malignant syndrome-like state in eight patients with parkinsonism
Rinshoshinkeigaku
Neuroleptic malignant syndrome. A pathogenetic role for dopamine receptor blockade?
Neurology
Neuroleptic malignant syndrome
Am J Psychiatr
Fatal hyperpyrexia after withdrawal of levodopa
Neurology
Hyperthermia after discontinuance of levodopa and bromocriptine therapy: impaired dopamine receptors a possible cause
Neurology
A neuroleptic malignant like syndrome due to levodopa therapy withdrawal
JAMA
Levodopa withdrawal syndrome identical to neuroleptic malignant syndrome
Postgrad Med J
Functional hyperthermia due to central dopaminergic impairment
Funct Neurol
Neuroleptic malignant-like syndrome following levodopa withdrawal
Rev Neurol (Paris)
Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy
Arch Intern Med
Neuroleptic malignant syndrome complicating levodopa withdrawal
Med J
Malignant hyperthermia and excitation–contraction coupling
Acta Physiol Scand
Molecular mechanisms of regulation of the activity of sarcoplasmic reticulum Ca-release channels (ryanodine receptors), muscle fatigue, and Severin's phenomenon
Biochemistry (Mosc)
Ca2+ release flux underlying Ca2+ transients and Ca2+ sparks in skeletal muscle
Front Biosci
Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia
Nature
Detection of a novel common mutation in the ryanodine receptor gene in the malignant hyperthermia: implications for diagnosis and heterogeneity studies
Hum Mol Genet
Hypothalamic pathology in the neuroleptic malignant syndrome
Am J Psychiatr
Muscle pathology in the neuroleptic malignant syndrome
Am J Psychiatr
Cited by (81)
Acupuncture for Parkinson's disease: From theory to practice
2022, Biomedicine and PharmacotherapyCitation Excerpt :However, patients are required to have a long treatment course to maintain the control effect. Once the drug is stopped, Parkinson's withdrawal malignant syndrome, which is conducive to the exacerbation of the disease [70], occurs. Further research needs to be undertaken to see whether we can avoid complications and MS caused by excessive supplements using acupuncture.
Adherence to treatment in Parkinson's disease: A multicenter exploratory study with patients from six Latin American countries
2021, Parkinsonism and Related DisordersCitation Excerpt :This study showed nonadherent patients have worse MDS-UPDRS Part III scores, higher prevalence of dyskinesias and OFF periods than adherent patients, a finding congruent with another multicenter European study [3]. The life-threatening complications involve a neuroleptic malignant syndrome associated with sudden withdrawal [26], which may associate an increased rate of hospitalizations and medical appointments, leading to higher health costs [27]. Various studies have determined risk factors for nonadherence in PD.
Parkinsonism hyperpyrexia syndrome
2018, NeurologiaNeuroleptic malignant syndrome: A neuro-psychiatric emergency: Recognition, prevention, and management
2017, Asian Journal of PsychiatryMalignant syndrome complicating enteral nutrition in Parkinson's disease – an important clinical pearl
2017, European Geriatric MedicineCitation Excerpt :Treatment is largely supportive and aimed at reversing triggering events. Left untreated the condition may result in serious complications such as rhabdomyolysis, and disseminated intravascular coagulation [4]. Various strategies have been suggested to decrease the potential drug-nutrient interaction between EN and dopaminergic therapy.
Parkinsonism Hyperpyrexia Syndrome following Deep Brain Stimulation
2015, Parkinsonism and Related Disorders